Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)
Status and phase
Conditions
Treatments
Details and patient eligibility
About
This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and second, to explore neurobiological mechanisms of action of guanfacine.
Full description
Subject population is comprised of 100 persons with PTSD. 50 patients will receive guanfacine and 50 patients will receive a placebo. Guanfacine is prescribed at 1 mg/day and may be increased to 2 mg/day. Samples of plasma MHPG will be collected weekly. Clinical ratings of PTSD anxiety and depression, as well as vital signs, will be assessed weekly. Repeated measures analysis of variance will assess significance of main effect of drug, time, and drug by time.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
- Males and females, age 18-65
- Diagnosis of PTSD from combat or civilian trauma
- No major medical problems such as diabetes, cardiovascular disease
- Taking no psychiatric medication, or taking only one SSRI antidepressant
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal